Results 51 to 60 of about 718 (128)

Effect of Star Topology Versus Linear Polymers on Antifungal Activity and Mammalian Cell Toxicity

open access: yesMacromolecular Bioscience, Volume 24, Issue 5, May 2024.
Synthetic polymers inspired by natural antimicrobial peptides have shown promise for the treatment of fungal infections. The present study compares linear to star‐like topology of amphiphilic, positively charged polymers. A low‐Xn 3‐arm polymer shows favourable activity against Candida spp. and biocompatibility with fibroblasts.
Sebastian Schaefer   +4 more
wiley   +1 more source

Recent advances and future perspectives in the pharmacological treatment of Candida auris infections

open access: yes, 2021
Introduction Candida auris is responsible for hospital outbreaks worldwide. Some C. auris isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.
Koehler, Philipp   +6 more
core   +1 more source

What is the role of microbial biotechnology and genetic engineering in medicine?

open access: yesMicrobiologyOpen, Volume 13, Issue 2, April 2024.
Microbial biotechnology, the technological application of microorganisms, has been instrumental in producing significant natural bioactive products. These include antibiotics, antifungals, anticancer drugs, antiparasitics, antivirals, immunosuppressants, toxoid vaccines, and therapeutic enzymes.
Fernando Santos‐Beneit
wiley   +1 more source

New and emerging options for management of invasive fungal diseases in paediatric patients

open access: yesMycoses, Volume 67, Issue 1, January 2024.
Abstract Invasive fungal diseases (IFDs) play an important role in the supportive care of paediatric patients with acute leukaemia and those undergoing allogeneic haematopoietic cell transplantation, and they are associated with significantly decreased overall survival rates in affected individuals.
Andreas H. Groll   +3 more
wiley   +1 more source

Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against Aspergillus fumigatus

open access: yesThe Cell Surface
Fosmanogepix is a new antifungal agent currently undergoing phase 3 clinical trials. Its active moiety, manogepix, inhibits Gwt1 which is an enzyme essential for the assembly and attachment of glycosylphosphatidylinositol anchors to cell wall proteins ...
Sean Brazil   +4 more
doaj   +1 more source

Disseminated Fusariosis, Leukemia Cutis, and Acute Sinus Disease in Prolonged Neutropenia from Acute Myeloid Leukemia

open access: yesJournal of Human Immunity
BackgroundPatients with acute myeloid leukemia (AML) and prolonged neutropenia are at high risk for invasive fungal infections such as fusariosis, which represents the second most common pathogenic mold infection in this population.
Katarzyna Karpinska-Leydier   +2 more
doaj   +1 more source

Non-Aspergillus molds

open access: yesJHLT Open
Non-Aspergillus molds, including Mucorales, Scedosporium, Lomentospora, and Fusarium species, are a significant cause of morbidity and mortality in heart and lung transplant recipients.
Emily M. Eichenberger, MD, MHS   +2 more
doaj   +1 more source

Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment

open access: yesJournal of Fungi
Aspergillosis is one of the most common fungal infections worldwide, caused by various species belonging to the genus Aspergillus, affecting both immunocompetent and immunocompromised individuals.
Carlos Alberto Castro-Fuentes   +5 more
doaj   +1 more source

Fusarium falciforme keratitis in a corneal transplant recipient treated successfully with fosmanogepix and intracameral amphotericin B

open access: yes
Background Ocular fungal infections are a major cause of vision loss worldwide. Fusarium spp., a leading cause of fungal keratitis, is often difficult to treat.
Alex Mainor   +7 more
core   +1 more source

A novel GWT1 A397T substitution combined with TAC1B F214I reduces manogepix susceptibility and fosmanogepix efficacy in Candida auris

open access: yes
Fosmanogepix (FMGX) is the prodrug of manogepix (MGX), which targets Gwt1, an inositol acyltransferase encoded by GWT1 and required for glycosylphosphatidylinositol anchor biosynthesis.
Tatsuro Hirayama   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy